Category: ACN Newswire

伊利诺伊州罗密欧维尔市, 2026年2月2日 - (亚太商讯 via SeaPRwire.com) - 高性能材料分销领导者福美拉今日宣布达成扩展分销协议，将赢创CARE品牌医疗级产品纳入其医疗产品组合。该协议覆盖美国和加拿大市场，为关键医疗应用领域的高性能聚酰胺材料开辟了全新渠道。此次扩展将于本周在MD&M West 2026展会启动，彰显双方通过高性能材料、响应式服务及稳定供应支持医疗市场的承诺。此举亦基于两家公司两年的合作基础——此前已将赢创VESTAMID®和TROGAMID®系列引入Formerra工程材料产品线。通过此次扩展，福美来将支持赢创医疗级材料的应用领域，涵盖流体处理、药物输送、诊断系统、手术器械部件、医疗器械外壳、短期人体接触部件（

MIAMI, FL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy.Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationwide fiber, mobile edge computing, and next-generation network architectures.Prior to Verizon, Mr. Vestberg spent nearly three decades at Ericsson, including almost seven years as its Chief Executive Officer, where he helped build and operate global infrastructure facilitating approximately 35% of worldwide mobile traffic.Mr. Vestberg's appointment comes at a time when AI adoption is increasingly constrained, not by software or silicon, but by power availability, cooling capacity, and deployment speed. Digipower X is working on addressing this challenge through the deployment of the AI-Ready Modular Solution (ARMS) platform, designed to deliver Tier-3 modular AI data centers within approximately 180 days, supported by a vertically integrated power strategy and a growing portfolio of large-scale energy assets."Hans Vestberg built and scaled the physical infrastructure that helped enable the fiber, mobile, and 5G revolutions," said Michel Amar, Chairman and Chief Executive Officer of Digipower X. "He understands what most of the market overlooks: AI's bottleneck isn't algorithms or chips, it's power, cooling, and deployment speed. Hans knows how to execute infrastructure transformation at a national and global scale, and we expect his guidance will be invaluable as we expand our modular AI data center footprint.""I've spent over 30 years building the networks that move data," said Mr. Vestberg. "The next decade is about building the infrastructure that processes it. Digipower X is more than just a data center company. It controls its power, is developing the ability to deploy Tier-3 infrastructure in the near term, and is building a modular platform to address the exact constraints holding back large-scale AI deployment. Its focus on power availability and deployment speed first, real estate second, is exactly the right approach."Infrastructure Experience Aligned with AI ScaleDuring his tenure at Ericsson (2010-2016), Mr. Vestberg led more than 115,000 employees worldwide and positioned the company at the forefront of next-generation wireless technologies. At Verizon (2018-2025), he reshaped the organization around a network-first strategy, oversaw major investments in spectrum and fiber, and advanced distributed edge-compute capabilities to enable data-intensive and latency-sensitive applications.Mr. Vestberg insightfully noted at Davos 2024 that "one of the most important infrastructures of this century is digital infrastructure," and that AI workloads will increasingly migrate from centralized hyperscale facilities toward distributed locations supporting real-time inference and enterprise demand.Mr. Vestberg currently serves as a board member of BlackRock and Verizon.Addressing the Power and Deployment Constraint in AI InfrastructureDigipower X operates a combined-cycle power plant and three additional operating sites, with more than 200 megawatts of power currently online. The Company has secured development capacity to support AI infrastructure expansion over the next three years, with the ability to develop up to an additional 1.5 gigawatts of power capacity, including at major sites in North Carolina and West Virginia.In West Virginia, Digipower X has entered into a letter of intent relating to a 1.3-gigawatt power plant, which is being evaluated as a long-term site for AI data center and advanced computing infrastructure deployment."Hans recognizes that national AI competitiveness depends on solving power availability and deployment speed," said Gerard Rotonda, Board Member of Digipower X and former CFO of Deutsche Bank Wealth & Asset Management Americas. "His experience aligns directly with Digipower X's mission to deliver infrastructure at the scale and speed this market now requires."Vestberg's Strategic FocusIn his advisory role, Mr. Vestberg will work closely with Digipower X's executive team on:AI infrastructure deployment strategy and scaling frameworks;Distributed and edge-compute architectures for inference-driven workloads;Strategic partnerships with hyperscalers, enterprises, and infrastructure stakeholders;Power optimization and energy-efficient data center design;Tier-3 redundancy and mission-critical reliability standards; andInternational expansion strategy and site prioritization.About Digipower XDigipower X is an innovative energy infrastructure company that develops Tier III-certified modular AI data centers and drives the expansion of sustainable energy assets.For further information, please contact:Michel Amar, Chief Executive OfficerDigipower X Inc.www.digipowerx.comInvestor RelationsT: 888-474-9222Email: IR@digihostpower.comCautionary StatementTrading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsExcept for the statements of historical fact, this news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company's expectations concerning the potential contributions by our new advisor to the Company's strategic efforts, the potential further improvements to profitability and efficiency across the Company's operations, including, as a result of the Company's expansion efforts, potential for the Company's long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company or at all; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; statements regarding the timing, scale and expansion of AI and high-performance computing infrastructure; changes in demand for AI and high-performance computing; future data center capacity may not be realized at the level anticipated by the Company, or at all; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company's filings at www.sedarplus.ca and www.SEC.gov/EDGAR. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, profitable use of the Company's assets going forward; the demand for data center capacity for AI and high-performance computing; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law.SOURCE: Digi Power X Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEEDHAM, MA, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.Under the agreement, research will be conducted at the University of Minnesota under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications.“This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform,” said David Platt, CEO of Bioxytran. “By leveraging the University’s deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline.”Research FocusThe sponsored research program will explore how specific polysaccharides and related carbohydrate structures interact with target molecules relevant to biological systems. Using state-of-the-art nuclear magnetic resonance methodologies, the research team will analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds. The work is expected to build on Bioxytran’s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.Academic–Industry CollaborationThe agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry. The University of Minnesota will carry out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions,” said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. “Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications.”Timeline and StructureThe research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program. In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran will receive broad rights to use the resulting research data for internal research and development purposes.Strategic SignificanceFor Bioxytran, the collaboration supports a broader strategy focused on strengthening its scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.The University of Minnesota continues to be recognized globally for its leadership in biomedical research and technology transfer, making it an ideal partner for companies seeking to bridge fundamental science and commercial development.About the University of MinnesotaThe University of Minnesota is one of the nation’s leading public research universities, known for its commitment to discovery, innovation, and the translation of research into real-world impact. Through industry partnerships and sponsored research programs, the University fosters collaboration that advances science and benefits society.About Bioxytran, Inc.Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.Company Contact:Bioxytran, Inc.75 Second Avenue, Needham, MA 02494Phone: 617‑454‑1199Email: info@Bioxytraninc.comWeb: www.Bioxytraninc.comForward-Looking StatementsThis press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月2日 - (亚太商讯 via SeaPRwire.com) - 君圣泰医药（2511.HK），一家专注于开发多功能创新疗法、以解决代谢性慢病未满足临床需求的创新药公司今日宣布，任命Filip Surmont博士为首席医学官，全面负责公司的医学战略、临床开发及相关医学事务，助力公司核心管线在心肾代谢系统疾病（CKM）领域的研发进展与价值提升。Filip Surmont博士在医疗与制药行业拥有超过30年的丰富经验，其中包括18年在跨国药企担任领导职务，以及16年的临床实践经验。他在心血管、代谢和肾脏疾病领域是全球公认的行业领导者，曾任职于惠氏、辉瑞、阿斯利康等跨国药企，担任高级医学领导职务，并在新兴市场、拉丁美洲、欧美及中国等多个地区领导医学事务工作，在复杂的全球医疗体系中成功打造高绩效团队，并推动多项临床实践变革。Filip Surmont博士职业生涯成就卓著。他助力达格列净成为重磅畅销药物；也曾在中国主导"ACT on HF"项目，成功让20万名心衰患者受益于指南推荐的标准治疗；他首创的哮喘"抗炎缓解剂（AIR）"治疗策略，影响了全球约5000万名患者，并推动了国际治疗指南的更新。作为国际权威医学专家，Filip Surmont 博士长期深耕代谢及心血管相关疾病研究并积累了深厚学术声望，多项研究发表于《The Lancet Diabetes & Endocrinology》、《Journal of the American College of Cardiology》等顶级期刊。在职业生涯早期，Filip Surmont博士曾为奥运级运动员提供医疗服务。Filip Surmont博士拥有比利时根特大学医学博士学位及运动医学硕士学位。君圣泰医药创始人、董事长兼首席执行官刘利平博士表示："我们热忱欢迎Filip Surmont博士正式加入君圣泰医药并担任首席医学官。他在心血管、代谢和肾脏疾病领域拥有丰富的全球经验、卓越的医学领导力与业界认可的成功经验。我们相信Filip Surmont博士的加入，将进一步强化公司的医学与临床开发能力，助力公司核心管线在CKM领域的临床开发与全球合作，为公司下一阶段发展注入强大动力。"君圣泰医药首席医学官Filip Surmont博士表示："我很荣幸加入君圣泰医药。君圣泰医药在代谢性疾病领域的研发策略与管线布局，尤其是核心产品在CKM领域的临床潜力，与当前全球代谢慢病的未满足医疗需求高度契合。我期待与团队紧密合作，促进公司创新药物的价值转化，为全球CKM患者带来全新的治疗选择。"关于君圣泰医药君圣泰医药（股票代码：2511.HK）是一家专注于代谢性慢病的创新生物医药公司，旨在开发多功能、多靶点的创新疗法，重点聚焦于解决心肾代谢系统疾病(CKM)。立足源头创新，公司致力于开发突破性疗法，为全球患者提供标本兼治、综合获益的解决方案。公司已建立100%自主知识产权的全球化产品管线，在多个国家和地区开展了针对多项适应症的临床研究。公司核心产品HTD1801已获得美国食品药品监督管理局（FDA）2项快速通道与1项孤儿药资格认定、以及十三五"重大新药创制"国家科技重大专项。更多信息，请访问公司官网：www.hightidetx.com，或联系公司品牌部：pr@hightidetx.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TSUKUBA, Japan, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Modern industry relies heavily on catalysts, which are substances that speed up chemical reactions. They’re vital in everything from manufacturing household chemicals to generating clean energy or recycling waste. However, designing new catalysts is challenging because their performance is affected by many interacting factors.A new tool uses a catalyst gene profiling, where catalysts are represented as symbolic sequences, making it easier for scientists to interpret data and design catalysts without a need for programming skills.A new tool developed by researchers at Hokkaido University, published in Science and Technology of Advanced Materials: Methods, will simplify the process by providing researchers with a way to easily view and explore data about catalysts, enabling them to identify patterns and relationships in catalyst datasets without needing advanced programming or computational skills.The tool takes advantage of an approach known as catalyst gene profiling, where catalysts are represented as symbolic sequences. This makes it easier for scientists to interpret the data and apply sequence-based analysis methods to design and improve catalysts. The tool itself is a web-based graphical interface that offers an intuitive and interactive way to investigate these catalyst profiles.“The system enables researchers to explore complex catalyst datasets, identify global trends, and recognize local features—all without requiring advanced programming skills,” explains Professor Keisuke Takahashi, who led the study. “By visualizing both the relationships among catalysts and the underlying gene-based features, the platform makes catalyst design more interpretable, accessible, and efficient, bridging the gap between data-driven analysis and practical experimental insight.”Users can view catalysts clustered together based on how similar their features are or how similar their sequences are. The tool also includes a heat map that offers insights into how the catalyst gene sequences are calculated. The different visualizations can be viewed side by side and are synchronized so they all update simultaneously when a user zooms in or selects a group of catalysts.The team plans to extend the tool to work with other material science datasets so it can be used more broadly in the field. They’re also working to include a predictive component. Integrating modeling and editing strategies would mean researchers could use the tool not only to explore existing catalysts but also to investigate new ideas for high-performance materials. In addition, they want to improve the tool’s collaborative features so that several researchers can work together to explore and annotate datasets, enabling a community-oriented, data-driven approach to material design and discovery.“Our goal is to make advanced materials research more intuitive, approachable, and impactful,” says Takahashi.Further informationKeisuke TakahashiHokkaido University keisuke.takahashi@sci.hokudai.ac.jpPaper: https://doi.org/10.1080/27660400.2025.2600689 About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-MDr Kazuya SaitoSTAM Methods Publishing Director SAITO.Kazuya@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Feb 1, 2026 - (ACN Newswire via SeaPRwire.com) - TCG.Zone (The Collectors Grid), a key player in the global collectibles infrastructure and ecosystem, has officially unveiled its strategic shift toward prioritizing investments in high-value, rare collectible assets. This strategic realignment underscores the company’s commitment to tapping into the long-term value and cultural significance of elite collectibles, with the recent participation in a high-profile international auction serving as a pivotal first step in this new direction.Recently, the world's only Pokémon card graded PSA 10 - Pikachu Illustrator - once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment.Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory.The Legendary Status of the World's Only PSA 10According to publicly available information, the world's only PSA 10 "Pikachu Illustrator" card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting.The Industry Significance of Goldin AuctionsAlthough Logan Paul's acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card's contemporary circulation and visibility. As one of the world's most influential high-end collectibles auction platforms, Goldin's auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market.Netflix Documentary Captures a Cultural MomentAmid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference.Global Participation and TCG.Zone's InvolvementThe discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand.Continuing to Follow the Card's Future TrajectoryIn post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world's only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value.The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting.About TCGThe Collectors Grid is an on-chain infrastructure designed to formalize collectibles as a structured asset class. By integrating provenance, ownership, pricing, and settlement at the protocol level, it addresses long-standing inefficiencies in the global collectibles market. The platform enables institutional-grade transparency while preserving the unique characteristics of collectible assets. Positioned as a settlement layer rather than a marketplace, The Collectors Grid provides the foundational rails for liquidity, valuation, and long-term capital participation in cards, IP, and high-value collectibles.Social LinksTwitter: https://x.com/tcgzoneofficialInstagram: https://www.instagram.com/tcgzoneofficial/Telegram: https://t.me/tcgzoneofficialMedia ContactBrand : The Collectors Grid (tcg.zone)Contact: AnnieWebsite: https://www.tcg.zone Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MOSCOW, Jan 31, 2026 - (ACN Newswire via SeaPRwire.com) - Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead.Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise "The Third Rome" and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations.Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades."By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society," Oreshkin said. "Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives."1. A New Global Economic Paradigm: Globalisation 2.0A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements."Globalisation hasn't ended; it has changed," Oreshkin said. "Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world."China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and "connector countries" like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy.2. Platformisation and Institutional AutomationThe second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond."Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms," Oreshkin said. "Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts."3. Transformation of the Global Financial SystemIt was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance."The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system," he said.4. Demographic Shifts and ChallengesThe fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services."Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%," Oreshkin explained. "Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other."5. Human Capital Development in the Technological EraThe final megatrend focuses on human capital in a rapidly changing technological environment.Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities."AI is both a challenge and an opportunity," Oreshkin said. "It allows personalized learning paths and supports teachers.Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era."Global PerspectiveThroughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands."The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future," Oreshkin concluded.Open Dialogue on AirThis year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna.First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually.Social LinksTelegram: https://t.me/gowithrussiaVK: https://vk.com/gowithrussiaOK: https://ok.ru/gowithrussiaDZen: https://dzen.ru/gowithrussiaContact for the mediaBrand: Russia National CentreContact: Media teamEmail: Pressa@russia.ru Website: https://russia.ruEssay Submission: https://dialog.russia.ru/en/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月31日 - (亚太商讯 via SeaPRwire.com) - 日清食品（香港）慈善基金（「慈善基金」）宣布连续第四年支持香港教育大学（「教大」）精英运动员，并举行2025/2026 学年日清食品精英运动员奖学金颁奖典礼，以表彰在各自运动领域中表现卓越、并立志成为未来教育工作者的七位精英运动员。该奖学金将支付整个修业期的全额学费，确保他们能够专注追求学业及运动目标，无须担心财务负担。该奖学金于2022年由日清食品（香港）慈善基金设立，以鼓励于教大修读健康教育（荣誉）学士课程、运动科学及教练（荣誉）理学士及学位教师教育文凭课程的精英运动员。此举措旨在支持他们的双轨事业发展，赋予他们能力成为合资格的健康教育工作者，同时在运动表现上继续追求卓越。2025/2026 学年的七名得奖者包括新晋及续期奖学金的精英运动员。四名新得奖的精英运动员分别是：铁人三项代表莫柏勋先生和黄柏尧先生、排球代表何健瑶小姐以及香港足毽队代表阎诺小姐。除了新的奖学金得主，慈善基金亦将该奖学金设为可续期形式，为精英运动员提供整个学习期间的资助支持。获得续期奖学金的三名精英运动员包括：前香港单车队代表蔡钧乐先生、赛艇代表陈柏匡先生及香港单车队代表刘睿哲先生。日清食品（香港）慈善基金主席安藤清隆先生表示：「日清食品在香港扎根逾 40 年，我们坚定不移地履行回馈社会的使命。奖学金直接体现了我们的创办人安藤百福先生『饮食和运动是健康的两大轴心』的理念。透过连续第四年支持教大的杰出运动员，我们不仅提供经济资助，更是在投资未来的领袖，他们将在我们的社会中倡导健康与福祉。我们很自豪能在他们的双轨发展道路上赋予他们力量，并深信他们将以杰出运动员和敬业教育工作者的双重身份，启发下一代。」香港教育大学副校长（研究与发展）陈智轩教授对长期的合作伙伴关系表达深切感谢。他表示：「教大致力推动精英运动员发展可持续的双轨事业路径。日清食品精英运动员奖学金的慷慨支持令我们能够让现役及退役运动员继续进修，同时认可了他们卓越的运动成就。我衷心祝贺所有奖学金得主，他们展现了极大的热情、决心和使命感，并诚挚感谢日清食品（香港）慈善基金及安藤先生对健康教育和精英运动员发展的巨大支持及信心。」主修中文及体育的学位教师教育深造文凭奖学金得奖人及杰出排球运动员何健瑶小姐对慈善基金表达衷心谢意。她说：「奖学金的支持赋予我们精英运动员学生力量，去追逐我们的抱负，并为社会带来有意义的影响。我们深信，我们能透过体育和教育的精神，创造更美好的未来。」图片说明日清食品（香港）慈善基金主席安藤清隆先生（中间右）及香港教育大学副校长（研究与发展）陈智轩教授（中间左）于2026年1月27日出席2025/2026学年日清食品精英运动员奖学金颁奖典礼。五名奖学金得主参与典礼，包括四名新得奖的精英运动员学生（从左至右）莫柏勋先生、黄柏尧先生、何健瑶小姐及阎诺小姐，以及获得续期奖学金的精英运动员学生蔡钧乐先生。 2025/2026年度日清食品精英运动员奖学金得奖人在各自领域均表现出色。左上起：铁人三项代表黄柏尧先生、排球代表何健瑶小姐、铁人三项代表莫柏勋先生、香港足毽队代表阎诺小姐、前香港单车队代表蔡钧乐先生、赛艇代表陈柏匡先生及香港单车队代表刘睿哲先生。关于日清食品（香港）慈善基金日清食品（香港）慈善基金（「慈善基金」）于2020年 9月由日清食品有限公司（股份编号： 1475）以信托契约的形式成立。慈善基金致力推动教育、教学、学习、艺术、科学和学术研究、援助有需要人士及进行惠及香港社区的慈善工作。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Jan 30, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone's real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's position in the field of skin health.Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3. The clinical studies information can be found on the Opzelura® official website, as follows:https://www.opzelura.com/opzelura-prescribing-information4. China Insights Consultancy’s industrial reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – As China’s first batch of Level 3 (L3) conditionally autonomous driving vehicles receives official market access, advanced smart driving is poised for its inaugural year of commercial explosion. At this pivotal juncture, Cheche Group Inc. (CCG) ("Cheche" or the "Company"), a leading global InsurTech platform, announced the signing of a strategic cooperation agreement with Volkswagen (Anhui) Digital Sales and Services Co., Ltd. (hereinafter "DSSO") and Beijing Cardif Airstar Property & Casualty Insurance Co., Ltd. (hereinafter "Cardif Airstar Insurance").This tripartite collaboration is more than just a deep dive into high-quality growth for New Energy Vehicle (NEV) insurance; it represents a core transition from "digitization" to "intelligence." The partnership establishes three strategic directions for synergy. First, it focuses on the transformation of product formats by leveraging Cheche’s SaaS platform to co-create an integrated "Insurance + Value-Added Services" package, enabling the efficient, one-stop fulfillment of high-value services. Second, it upgrades pricing capabilities by deeply integrating compliant driving data with dynamic vehicle information, utilizing AI-driven risk profiling to achieve differentiated precision pricing while addressing the complex challenge of liability determination in human-machine co-driving scenarios. Finally, it expands the ecosystem dimension by embedding insurance services throughout the vehicle sales and after-sales process, extending the business from a single policy to a full-lifecycle service ecosystem that encompasses renewal management and mobility protection.01. Smart Driving Insurance: Securing "Pricing Authority" in the L3 Mass Production EraTraditional auto insurance has long struggled with "human-machine co-driving" scenarios due to a lack of real-time dynamic data for liability determination and precise risk identification. Having served leading automakers such as Tesla, Li Auto, and Xiaomi, Cheche provides VW Anhui Digital with an embedded SaaS system centered on data attribution and dynamic pricing.Through this SaaS infrastructure, vehicle driving data is seamlessly synchronized with BNP Paribas Star’s actuarial models. This AI-driven joint risk profiling not only resolves the technical difficulties of liability judgment in smart driving scenarios but also delivers a "low-premium rewards for safe drivers," serving as a vital solution to the profitability challenges currently facing the NEV insurance industry.02. Ecosystem Breakthrough: Leveraging the "Xiaomi + Volkswagen DSSO" New Quality Productive ForcesInvestors are closely watching the cross-sector dynamics underpinning this collaboration. Cardif Airstar Insurance was co-founded by Xiaomi Group, Volkswagen Financial Services, and Cardif Airstar Insurance, combining the strengths of an internet giant, a global financial powerhouse, and a leading smart automaker.As the hub connecting these forces with Volkswagen’s Hefei Intelligent Electric Vehicle Center, Cheche is penetrating the world’s top smart driving supply chains. This is not merely system integration; it marks Cheche’s evolution into a digital operator within the "Vehicle-Battery-Charging-Insurance" integrated landscape. Amid policy tailwinds such as "New Quality Productive Forces," Cheche’s closed-loop ecosystem is becoming a definitive growth pole for insurance and tech capital.03. Scenario Transformation: From Transactional Policies to Full-Lifecycle OperationsIn 2026, as the automotive market shifts from a competition over hardware parameters to a competition over user experience, Cheche is helping DSSO deeply couple insurance services with the car-buying and after-sales journey. The integrated service package transforms insurance from a low-frequency tool into a high-frequency touchpoint for user engagement.Christian Koenig, After-sales Director of DSSO, noted that Cheche’s technical foundation allowed the partnership to advance rapidly from a high starting point. This "plug-and-play" empowerment capability, proven by mainstream automakers, has become a technical moat for Cheche in the capital markets.04. Conclusion: The Final Piece of the Trillion-Dollar Blue OceanThe year 2026 marks the point where NEV insurance evolves from scale expansion to intelligent upgrades. Cheche will continue to advance its AI pricing engine, driving the leap from digital to intelligent services.According to data released by the Ministry of Public Security on January 26, China’s NEV ownership reached 43.97 million units by the end of 2025, accounting for 12.01% of the total vehicle population—a growth rate exceeding 40% year-over-year. In this environment, those who define the insurance standards for the smart driving era will control the entry point to future mobility. With its high barriers to entry via OEM partnerships and forward-looking AI layouts, Cheche is racing toward becoming a leader in the trillion-dollar NEV insurance market. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – 27 January 2026, Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for elite athletes from The Education University of Hong Kong (“EdUHK”) for the fourth consecutive year. The Presentation Ceremony for the Nissin Foods Scholarship for Elite Athletes 2025/2026 was held to honour seven outstanding athletes who not only demonstrate excellence in their respective sports but also aspire to become future educators. The scholarship will cover their full tuition fees throughout their entire study period, enabling them to pursue their academic and athletic goals without financial concerns.Established in 2022 by the Nissin Foods (Hong Kong) Charity Fund, the scholarship is designed to encourage elite athletes enrolled in the Bachelor of Health Education (Honours), Bachelor of Science (Honours) in Sports Science and Coaching, or the Postgraduate Diploma in Education programme at EdUHK. The initiative aims to support their dual career development, empowering them to become qualified health educators while continuing to strive for excellence in their athletic performance.The seven awardees for the 2025/2026 academic year include new and renewing recipients. The four new awardees are: Mr. MOK Pak Fan (triathlon), Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), and Miss YAN Nuo (shuttlecock). In addition to welcoming new scholars, the Charity Fund also made the scholarship renewable to support the elite athletes throughout their study period. The three recipients of the renewed scholarship are: Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, “Having been deeply rooted in Hong Kong for over four decades, Nissin Foods is steadfast in its mission to give back to the community. This scholarship is a direct reflection of our founder Mr. Momofuku Ando’s philosophy that ‘Eating and sports are the two axles of health.’ By supporting these talented athletes at EdUHK for the fourth year, we are not just providing financial support, we are investing in future leaders who will champion health and wellness in our society. We are proud to empower them on their dual career path, confident that they will inspire the next generation as both accomplished athletes and dedicated educators.”Expressing his profound gratitude for the long-standing partnership, Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK, said, “EdUHK is dedicated to promoting sustainable dual-career pathways for high-performance athletes. The generous Nissin Foods Scholarship for Elite Athletes allows us to support both active and retired athletes in advancing their educational pursuits, while also recognising their exceptional sporting accomplishments. I would like to extend my heartfelt congratulations to all the scholarship recipients, who demonstrated great passion, determination, and a sense of mission, and sincerely thank the Nissin Foods (Hong Kong) Charity Fund, and Mr Ando for the tremendous support and confidence in health education and the development of elite athletes.”Accomplished volleyball player Miss HO Kin Yiu, recipient of the scholarship from the Postgraduate Diploma in Education, majoring in Chinese and Physical Education, shared her heartfelt appreciation to the Charity Fund, “The support of the scholarship empowers us, as elite athlete-students, to chase our aspirations and make a meaningful influence on society. We are confident that we can help create a brighter future through the spirit of sports and education.”PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK (middle left), attended the Presentation Ceremony for Nissin Foods Scholarship for Elite Athletes 2025/2026 on 27 January 2026. Five scholarship recipients attended the ceremony, including four new awardees for the 2025/2026 academic year, namely: (from left to right) Mr. MOK Pak Fan, Mr. WONG Pak Yiu, Miss HO Kin Yiu, and Miss YAN Nuo, as well as the renewed awardee - Mr. CHOI Kwan Lok. Awardees of the Nissin Foods Scholarship for Elite Athletes 2025/2026 are achieving great success in their individual disciplines. From top left: Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), Mr. MOK Pak Fan (triathlon), Miss YAN Nuo (shuttlecock), Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年1月30日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）已于2026年1月30日获得中国国家药品监督管理局（NMPA）批准磷酸芦可替尼乳膏（白癜风适应症）（"产品"）新药上市许可申请（NDA）。产品用于治疗12岁及以上儿童和成人患者伴面部受累的非节段型白癜风，是中国批准的首款且唯一用于白癜风治疗的靶向药，满足巨大未被满足的临床需求。磷酸芦可替尼乳膏是经美国食品和药物管理局（FDA）及欧洲药品管理局（EMA）批准的首款也是唯一一款用于非节段型白癜风复色的药物[1,2]，在产品正式获得NDA批准之前，康哲药业受益于国家赋予海南自由贸易港及乐城先行区（"乐城先行区"）"先行先试"政策、"港澳药械通"政策、北京市及天津自贸试验区的临床急需进口药品政策，已启动磷酸芦可替尼乳膏的试点应用。目前博鳌超级医院已为超7,000名非节段型白癜风患者开具磷酸芦可替尼乳膏处方，且广州、深圳、东莞、佛山、中山、珠海、江门、惠州、北京及天津共二十余家医院已提供该药品处方服务，体现了其临床价值。产品在境外临床研究与中国真实世界研究中均展现出积极结果：其在境外开展的两项相同设计的III期双盲、随机、安慰剂对照研究（TRuE-V1和TRuE-V2）中，产品治疗24周后达到主要疗效指标面部白癜风面积评分指数改善至少75%（F-VASI 75）的患者比例均为29.9%，显著高于安慰剂组的7.5%和12.9%，持续使用至52周，复色效果持续[3]。根据乐城先行区药品真实世界数据应用试点项目有关规定，磷酸芦可替尼乳膏在中国开展真实世界研究，疗效积极，与境外关键临床研究结果一致。境内外临床研究中所有的次要疗效指标均显示出与主要疗效指标一致的获益趋势，且白癜风治疗效果随疗程延长持续改善。同时，根据乐城先行区安全性监测数据，未发现新的安全性事件，未发生导致停药或退出的不良事件（AE），未发生研究药物相关的严重不良事件（SAE）。此次产品白癜风适应症获批，将为国内千万白癜风患者带来治疗新希望，满足市场迫切的临床需求。同时，产品将进一步丰富德镁医药在皮肤治疗领域的产品矩阵，并有望与现有处于商业化阶段的创新药益路取（替瑞奇珠单抗注射液）、独家药喜辽妥（多磺酸粘多糖乳膏），以及系列在研创新药和皮肤学级护肤品等在专家网络与市场资源等方面产生协同，提升德镁医药在皮肤健康领域的地位。此外，康哲药业于中国开展的磷酸芦可替尼乳膏治疗轻中度特应性皮炎患者的III期临床试验，已取得阳性结果。截至目前，康哲药业正在中国积极推进磷酸芦可替尼乳膏治疗特应性皮炎的新药上市申请，如若获批上市，将为中国广大特应性皮炎患者群体提供新的治疗选择。关于白癜风适应症白癜风是一种慢性自身免疫性疾病，其特征是皮肤色素脱失，其发病原因为产生色素的细胞即黑素细胞的缺失。据估算，中国约有1030万人患有白癜风，其中约820万人患有非节段型白癜风[4]。现有疗法，如外用糖皮质激素（TCS）及外用钙调神经磷酸酶抑制剂（TCIs）存在临床缺陷，长期用药有不良反应或疗效有限。磷酸芦可替尼乳膏NDA获批，成功填补了白癜风靶向药物治疗的空白，具有重大标志性意义。关于磷酸芦可替尼乳膏的更多信息磷酸芦可替尼乳膏（Opzelura®）是Incyte开发的选择性JAK1/JAK2抑制剂芦可替尼制成的一种创新型乳膏，在美国获批用于局部治疗成人及12岁及以上患者的非节段型白癜风，及2岁及以上非免疫力功能低下患者的轻度至中度特应性皮炎的局部短期和非连续性慢性治疗。在欧洲，磷酸芦可替尼乳膏被批准用于治疗成年及12岁及以上青少年面部受累的非节段型白癜风。康哲药业于2022年12月2日，通过德镁医药的附属公司与Incyte就磷酸芦可替尼乳膏订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一囯（"区域"）研发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将磷酸芦可替尼乳膏除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。Incyte拥有磷酸芦可替尼乳膏全球开发和商业化权利，在美国及欧洲以Opzelura®的名称销售。Opzelura®和Opzelura®标识是Incyte的注册商标。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.FDA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2.EMA批准信息可在Incyte官网查询，网址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3.相关临床研究信息可在Opzelura®官网查询，网址：https://www.opzelura.com/opzelura-prescribing-information4.数据来自灼识咨询报告康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和-医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PUTNAM, CT AND ROMEOVILLE, IL, Jan 29, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions.Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials."Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Building on the momentum of our Americas partnership, we're excited to extend these proven solutions to European customers who demand the highest standards in medical device materials."With more than 30 years in custom medical polymer compounding, Foster delivers highly engineered, top-of-the-polymer-pyramid formulations tailored to demanding requirements. The portfolio includes options such as radiopaque compounds and grades that meet USP Class VI requirements and align with ISO 10993 expectations. These materials support critical end uses across the healthcare space, including implantable products and other highly specialized applications."Extending our Foster portfolio into Europe with Formerra allows us to meet growing demand from healthcare manufacturers in one of the world's most dynamic medical device markets," said Arthur Adams, Chief Commercial Officer, GEON. "This expansion reinforces our shared commitment to supporting innovation in life-saving applications globally."Adding Foster® compounds to its European portfolio will enable Formerra to better serve customers in the healthcare space, offering not only access to highly engineered medical polymers, but also deep regulatory expertise and responsive logistics across the region.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, February 3-5, 2026.Key DetailsFormerra will distribute Foster® medical compounds in Europe.This agreement adds custom medical-grade compounds to Formerra's existing global access to GEON® PVC and filled PP materials.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways - driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About GEON Performance SolutionsGEON® Performance Solutions unlocks the power of polymers for the future. From biomedical materials from our medical division, Foster, LLC, to building materials, automotive, connectivity, and appliances, customers in these markets rely on the portfolio of compounding solutions, highly adaptable vinyl, polyolefin, engineered resin technologies, and full-service contract manufacturing that we deliver. In every formulation, collaboration, and challenge we're shaping the brilliance of tomorrow and providing a formidable advantage by engineering what's possible. Geon has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. Geon is a portfolio company of SK Capital Partners.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – A growing number of robotics and artificial intelligence companies backed by Shoucheng Holdings Limited are set to appear at China’s 2026 CMG New Year’s Gala, reflecting the investor’s expanding footprint across the country’s emerging automation and embodied intelligence sectors.The latest company to confirm its participation is Noetix Robotics, according to recent announcements. Shoucheng Holdings led the company’s financing round in 2024 and has continued to increase its investment through subsequent rounds, making it Noetix Robotics’ largest external investor, people familiar with the matter said.Noetix Robotics’ appearance adds to a lineup that already includes other Shoucheng-backed firms. Unitree Robotics, known for its quadruped and humanoid robots, was earlier named a robot partner of the 2026 Gala, marking its third appearance on the program. Beijing Galbot Co., Ltd., which focuses on embodied artificial intelligence systems, has also been designated by China Media Group as the Gala’s embodied large-model robot.The clustering of multiple portfolio companies on the same edition of the Gala places Shoucheng Holdings among a small group of investors with broad representation on one of China’s most-watched annual broadcasts. The event, which regularly draws hundreds of millions of viewers, has increasingly been used as a platform to highlight advances in artificial intelligence, robotics and advanced manufacturing.China Media Group, the organizer of the Gala, has in recent years expanded the role of technology-focused programming, aligning with national policy priorities around intelligent manufacturing and industrial upgrading. While participation in the Gala does not directly translate into revenue, companies and investors see it as an important signal of technical maturity and policy relevance.Unitree Robotics’ repeated appearances underscore this dynamic. The company has previously used the Gala to demonstrate improvements in motion control, balance and coordination, capabilities that are critical as robots move from laboratory environments into commercial and industrial settings. Its continued inclusion suggests confidence in its engineering progress and deployment readiness.Galbot’s designation as the Gala’s embodied large-model robot reflects a broader shift in focus from mechanical performance alone to systems that integrate perception, reasoning and physical execution. Embodied artificial intelligence—where large models are combined with real-world robotic interaction—has become a priority area for Chinese research institutions and technology companies as generative AI expands beyond software applications.The addition of Noetix Robotics introduces another layer to the lineup. The company concentrates on robotic power systems and core engineering components, segments that are increasingly viewed as strategic as China seeks to reduce reliance on imported technologies and strengthen domestic supply chains. Shoucheng Holdings’ sustained backing of Noetix Robotics highlights an investment strategy that spans both complete robotic systems and foundational hardware.Shoucheng Holdings has steadily increased its exposure to robotics over the past several years, backing companies involved in full-stack robotics, embodied intelligence and critical components. Rather than focusing on a single technological approach, the firm has adopted a portfolio strategy that combines capital investment with access to application scenarios and commercialization platforms.One such platform is the Shoucheng Robot Tech Experience Store, a robotics-focused retail and demonstration network operated by the company. While not all Gala participants are Shoucheng investees, some companies, including MagicLab Robotics Technology (Wuxi) Co., Ltd., have placed products such as robotic dogs within the platform’s offline spaces for demonstrations and user engagement. MagicLab was named a strategic intelligent robotics partner for the Year of the Horse CMG New Year’s Gala earlier this year.By linking high-profile media exposure with physical demonstration and sales environments, Shoucheng Holdings aims to accelerate the transition from technology showcase to market adoption, according to people familiar with the platform’s positioning. The approach mirrors a broader trend among Chinese industrial investors to combine financial backing with scenario-based deployment.Industry analysts say the concentration of Shoucheng-backed companies on the 2026 Gala stage illustrates how China’s robotics sector is evolving from isolated prototypes toward more integrated industrial ecosystems. The presence of companies spanning full robotic platforms, embodied intelligence and core engineering components suggests increasing specialization and coordination across the value chain.As preparations for the 2026 CMG New Year’s Gala continue, robotics and artificial intelligence are expected to remain central themes. For Shoucheng Holdings, the event offers a snapshot of how its investments are converging on a national platform, reflecting a strategy that has shifted from selective bets to a broader, system-oriented approach to industrial technology.While the commercial impact of Gala exposure is difficult to quantify, market participants increasingly view the lineup as an indicator of which technologies and companies are gaining momentum within China’s rapidly changing AI and automation landscape. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – Quam Plus International Financial Limited ("Quam Plus Financial" or the "Group") is delighted to announce the successful conclusion of the "3rd Hong Kong Capital Markets Forum 2026" held at the Grand Hyatt Hong Kong. The Group is honored to be one of the Gold Sponsors of this prestigious event. Dr. Kenneth Lam, CEO of the Group, who also serves as Chairman of the Forum Organizing Committee cum Executive Deputy Chairman of The Chamber of Hong Kong Listed Companies (CHKLC), led a delegation of senior management to attend the forum. Mr. Paul Chan Mo-Po, GBM, GBS, MH, JP, Financial Secretary of the Government of HKSAR were also in attendance. Together with prominent figures from the capital markets, government, academia, and the financial sector, they engaged in in-depth discussions on further strengthening Hong Kong's economic momentum.The forum was jointly organized by Hong Kong Association of Registered Public Interest Entity Auditors Limited (PIEAA), The Chamber of Hong Kong Listed Companies (CHKLC), The Hong Kong Institute of Directors (HKIoD), and the Association of Hong Kong Capital Market Practitioners Limited (HKCMP), with strong support from key institutions including Hong Kong Exchanges and Clearing Limited (HKEX), the Securities and Futures Commission (SFC), and the Accounting and Financial Reporting Council (AFRC).As the global economy enters a new cycle of innovation and transformation, this year's forum, themed "Capturing the Next Growth Momentum” explored how Hong Kong can reinvent itself amid a rapidly changing international financial landscape, rebuild confidence, and transform challenges into powerful drivers of progress.As the globalMr. Paul Chan Mo-Po, GBM, GBS, MH, JP, served as the Guest of Honour and delivered the keynote address. He stated: "In my view, the global environment is shifting in ways that create new and favourable opportunities for Hong Kong. Our challenge is how to seize the moment and deliver tangible outcomes. More specifically, that involves supporting the country's high-quality development; matching the needs of Mainland enterprises going global and the appetite of international investors; and, at the same time, driving Hong Kong's own growth."Dr. Kenneth Lam, in his capacity as Chairman of the Forum Organizing Committee, delivered the opening remarks: "As a vital financial hub connecting China and the world, our mission is to strengthen confidence, deepen integration, and expand diverse growth engines. We must keenly identify the next wave of growth drivers and ensure that markets advance in a balanced manner between flexibility and integrity. Positioned at the core of global transformation, this forum reminds us once again that progress is never accidental—it stems from resolute choices: with innovation as our aspiration, collaboration as our bridge, and conviction as our strength, we can lead Hong Kong forward and open up new chapters."Hong Kong now stands at the heart of global change. Advancing the capital markets requires not only visionary policies and regulation but also active participation and collaboration from all sectors. This year's forum focused on two key themes—digital asset development and capital market structural reform—examining how technological innovation can coexist with trust to drive reforms that build greater market resilience.As a proud Gold Sponsor of this year's forum, Quam Plus Financial looks forward to working hand in hand with all stakeholders, including central government offices in Hong Kong and other parties, to propel Hong Kong and the region toward new achievements. Together, we aim to seize new opportunities, activate new momentum, and march toward a high-quality, sustainable financial future.About Quam Plus International Financial LimitedQuam Plus International Financial Limited (the “Company”, Stock Code: 00952.HK) is a Hong Kong based financial services group which is listed on the Main Board of the Stock Exchange of Hong Kong Limited. The Company was publicly listed in Hong Kong in 1997, it is committed to building a comprehensive, full-licensed integrated financial platform. The core businesses of the Company are brokerage business, interest income business, corporate finance business, asset management business and investments and other businesses. The Company strives to become the ideal partner for both corporate and individual investors in Hong Kong and China. The Company also offers premier one-stop financial services to its clients. The Company continued to provide capital markets services through its representative office or the wholly-owned foreign enterprise in Shenzhen, Shanghai, Shenyang, Ningbo, Beijing, Chengdu, Hangzhou and Xiamen of the PRC and through its networks of Global Alliance Partners network and Oaklins International.For further information, please contact:Quam IR LimitedMandy Lo Tel: (852) 2217-2753 Email: mandy.lo@quamgroup.comCharlie Chan Tel: (852) 2217-2504 Email: charlie.chan@quamgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com